Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma

Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma

Glypican-3 (GPC3) is expressed in 75% of hepatocellular carcinoma (HCC), but not normal liver, making it a promising HCC therapeutic target. GC33 is a full-length humanized monoclonal IgG1 specific to GPC3 that can localize to HCC in vivo. GC33 alone failed to demonstrate therapeutic efficacy when e...

Full description

Bibliographic Details
Main Authors: Meghan M. Bell, Nicholas T. Gutsche, A. Paden King, Kwamena E. Baidoo, Olivia J. Kelada, Peter L. Choyke, Freddy E. Escorcia
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Molecules
Subjects:
targeted alpha particle therapy
hepatocellular carcinoma
glypican-3
Online Access:https://www.mdpi.com/1420-3049/26/1/4

Internet

https://www.mdpi.com/1420-3049/26/1/4

Similar Items